The FDA has approved Cequa for the treatment of dry eye disease, Sun Pharmaceutical Industries announced in a press release.
Cequa (cyclosporine ophthalmic solution 0.09%), the highest FDA-approved concentration of cyclosporine A and the first to incorporate nanomicellar technology, is indicated to increase tear production, the release said.
“Dry eye disease represents an area of high unmet medical need, with a significant number of patients who are currently untreated,” Abhay Gandhi, Sun Pharma North America CEO, said in the release. “The U.S. FDA approval of Cequa represents
Uncategorized